[12] Patent
[11] Patent No.:GC0011371  
[45] Date of Publishing the Grant of the Patent: 1/Sep /2020                64/2020  		 Number of the Decision to Grant the Patent:2020/171406
Date of the Decision to Grant the Patent:27/Jul/2020

[21] Application No.:GC 2013-35777

[22] Filing Date:26/1/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
CN
26/1/2012
10/7/2012
14/12/2012
 61/591001
61/669902
PCT/CN2012/086703

[72] Inventors:1- Pascal Furet،2- Vito Guagnano،3- Philipp Holzer،4- Joerg Kallen،5- Robert Mah،6- Keiichi Masuya،7- Achim Schlapbach،8- Stefan Stutz،9- Andrea Vaupel،10- Lv Liao،11- Liang Mao

[73] Owner: Novartis AG, Lichtstrasse 35, 4056, Basel, Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

   

[51]IPC:
Int. Cl.: A61K 31/4188; A61P 35/00; C07D 487/04 (2006.01)

[56] Cited Documents:

-US 2003/153580 A1 (KONG NORMAN [US] ET AL) 14 August 2003
-US 2011/230457 A1 (BERGHAUSEN JOERG [CH] ET AL) 22 September 2011
 
Examiner: PH. Sarah A. AlGrainies

[54] Imidazopyrrolidinone compounds
[57] Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
No. of claims: 15     No. of figures: 7


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.